Philips, Hologic announce new partnership focused on women’s health

Royal Philips and Hologic have announced a new multi-year global partnership that combines Philips’ large portfolio of imaging systems and services with Hologic’s mammography technologies. Financial details have not been disclosed at this time.

“No two women are alike, and we are teaming up with care providers and leading industry partners to support the delivery of a tailored, seamless breast care experience for women,” Rob Cascella, CEO of diagnosis & treatment businesses for Royal Philips, said in a prepared statement. “That is why I am very pleased to announce our new partnership with Hologic for mammography. This partnership allows us to offer a complete set of innovative diagnostic imaging systems, software and services to our customers, including Hologic’s market-leading mammography solutions for breast screening and diagnosis of women in need of care.”

“Our market-leading mammography solutions perfectly complement Philips’ portfolio, making Hologic the right industry partner for this first-of-its-kind collaboration,” Pete Valenti, Hologic’s division president of breast and skeletal health solutions, said in the same statement. “Now, through the partnership, Hologic can join Philips when engaging with customers on projects that were not previously possible for the two companies alone. It’s a win for everyone involved, including the customers and patients we serve.”

Through the agreement, Philips will be making certain Hologic breast health solutions available to hospitals and health systems.

Both companies are currently at the European Congress of Radiology 2018 in Vienna. Hologic is displaying at booth #211 in X2 and Philips is at booth #402 in X4.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.